Ho Yeong Lim

Research interests

Publications

• Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

  The Lancet Oncology · 2023 · 10.1016/s1470-2045(23)00469-2

• Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

  Journal of Hepatology · 2021 · https://doi.org/10.1016/j.jhep.2021.11.030

• Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

  Journal of Clinical Oncology · 2021 · 10.1200/jco.20.03555

• IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).

  Journal of Clinical Oncology · 2021 · 10.1200/jco.2021.39.3_suppl.267

• Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial

  The Lancet Oncology · 2021 · 10.1016/s1470-2045(21)00151-0

• Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1915745

• Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

  British Journal of Cancer · 2020 · https://doi.org/10.1038/s41416-020-0802-1

• A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆

  Annals of Oncology · 2020 · 10.1016/j.annonc.2020.11.017

• Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(18)30937-9

• Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.19.01307

• Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma

  Annals of Oncology · 2018 · 10.1093/annonc/mdy101

• Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

  Nature Medicine · 2018 · https://doi.org/10.1038/s41591-018-0101-z

• Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma

  Journal of Clinical Oncology · 2017 · 10.1200/jco.2017.73.5324

• Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses

  Journal of Clinical Oncology · 2015 · 10.1200/jco.2014.58.3930

• Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib

  JAMA · 2014 · 10.1001/jama.2014.7189

• Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2012.44.5643

• Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

  Nature Medicine · 2013 · 10.1038/nm.3089

• Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2013.50.3961

• Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone

  Journal of Clinical Oncology · 2012 · 10.1200/jco.2011.39.4585

• Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study

  The Lancet Oncology · 2011 · 10.1016/s1470-2045(11)70301-1

• Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2011.36.2236

• Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

  The Lancet · 2011 · https://doi.org/10.1016/s0140-6736(11)61613-9

• Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2011.39.1953

• Increased expression of cyclooxygenase-2 protein in human gastric carcinoma.

  PubMed · 2000

• Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.

  PubMed · 1997

Current projects

No projects listed.